StockNews.com Initiates Coverage on TRACON Pharmaceuticals (NASDAQ:TCON)

StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research report released on Wednesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Trading Down 41.0 %

TRACON Pharmaceuticals stock opened at $0.04 on Wednesday. The firm has a market capitalization of $119,350.00, a PE ratio of 0.01 and a beta of 1.43. TRACON Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $14.75. The firm has a 50-day moving average price of $0.09 and a 200-day moving average price of $0.60.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.